The wide-ranging executive order signed by Trump aims to reduce healthcare costs. It comes one day after the Trump ...

The pharmaceutical giant scrapped development of a once-daily GLP-1 pill after a person involved in the drug’s trial suffered ...

PARIS (Reuters) -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

A key vaccine advisory committee is meeting for the first time under new U.S. Health Secretary Robert F. Kennedy Jr., a ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

Pfizer decided to abort the clinical trial of its daily weight loss pill 'Danuglipron' after one patient in a trial showed signs of liver damage, likely to be caused by the drug.

Crib mattresses have been found to emit toxic chemicals while children sleep, according to a new study, and could lead to ...

New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

The price of pharmaceuticals will likely go up soon, and generics are poised to be hit the hardest.

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.